Manufacturing feasibility assessment
5. Verdict
Home sperm storage requires validated cryogenic logistics and regulated donor handling, impossible at $150–300 globally; pivot to a non-storage applicator using clinic-thawed samples and pursue local
6. Subsystems
- 6.1 Semen cartridge and fluid pathHIGH
- 6.2 Home cryopreservation and storageHIGH
- 6.3 Reusable delivery applicatorHIGH
- 6.4 Sterility and cross-contamination controlHIGH
- 6.5 Temperature sensing and controlsMEDIUM
- 6.6 Regulatory and tissue-chain complianceHIGH
7. Bill of materials
| Item | 100 | 1,000 | 10,000 |
|---|---|---|---|
| 7.1 Reusable applicator body, pump and seals | $110–150 | $75–100 | $45–65 |
| 7.2 Single-use sterile cartridge and barrier pack | $40–60 | $25–35 | $14–22 |
| 7.3 Controlled-rate freezing / cryogenic cooling module | $650–950 | $440–650 | $280–430 |
| 7.4 Cryogenic containment, insulation and safety hardware | $180–300 | $125–200 | $75–125 |
| 7.5 Sensors, controller, battery and charging components | $60–95 | $40–60 | $25–40 |
| 7.6 Assembly, functional test, packaging and traceability labels | $75–120 | $45–70 | $30–48 |
| 7.7 Total estimated COGS | $1,115–1,675 | $750–1,115 | $469–730 |
At 10,000 units, tooling alone adds about $120–250 per unit. Estimated 10k COGS of $469–730 already exceeds the full $150–300 retail target and the $120 maximum BOM threshold at $300 retail.
8. Gates to clear
8.1 [DFM]
A home “icing” system cannot reliably preserve sperm. Valid cryopreservation requires controlled-rate freezing, qualified cryoprotectant handling and liquid-nitrogen storage; the proposed cartridge format also has leakage and cross-contamination risk.
Path: Blocked as proposed. Viability would require removing home freezing and long-term storage, with sperm prepared, frozen, released and cold-chain shipped only by a licensed sperm bank or andrology laboratory. Redesign the consumer article as a sterile, single-use transfer applicator with no sperm-filled cartridge sold direct.
8.2 [Certification]
Global sale has no single certification route. In the US, donor-sperm handling engages FDA human cells, tissues, and cellular and tissue-based product requirements under 21 CFR 1271, while the delivery device may require FDA device review. In the EU, reproductive-tissue handling is governed through the Human Tissue and Cells framework and the device requires EU MDR 2017/745 conformity assessment and CE marking.
Path: Blocked for a direct-to-consumer global sperm-cartridge and home-storage model. A viable sequence would be US FDA regulatory classification/pre-submission with a licensed tissue establishment, then EU MDR classification with a Notified Body and separate authorised tissue-establishment partners in each EU market. Country-specific launches would still be required.
8.3 [Tooling]
Even at 10k units, the credible cryogenic system BOM is $469–730, versus a maximum allowable BOM of $120 at the top $300 retail price under the stated 40% criterion. Tooling amortisation adds $120–250 per unit at 10k units.
Path: Blocked at the stated retail price. Economics would require eliminating the cryogenic subsystem, moving all sperm storage and release to licensed fertility providers, using a low-cost single-use sterile applicator, and setting any reusable device price only after validating service-partner and regulatory costs.
9. Prototype sequence
- 9.1Define the exact intended use, sperm ownership model, storage duration, countries of sale and whether the product delivers vaginally or makes an intrauterine insemination claim.These decisions determine whether the concept is a consumer product, medical device, regulated reproductive-tissue service, or a combination of all three.
- 9.2Engage an andrology laboratory and reproductive-tissue regulatory counsel to map sperm viability, cryopreservation, donor-screening and chain-of-identity requirements.This establishes whether any claimed home storage process is scientifically valid before industrial design and tooling investment.
- 9.3Build non-biological fluid-path prototypes and perform leakage, cleaning, cartridge connection, dose-repeatability and misuse testing.This can identify mechanical failure modes without handling human biological material in an unqualified product-development setting.
- 9.4Run a controlled thermal feasibility study through a qualified andrology lab using its approved research processes and compare results with laboratory cryopreservation controls.The study will confirm that home icing is not an acceptable substitute for validated cryopreservation and quantify the required process infrastructure.
- 9.5If pursuing a commercial route, pivot to a clinic- or sperm-bank-dispensed, single-use sterile transfer applicator with no home freezing or direct sperm-cartridge sales.This removes the principal scientific, regulatory and cost blockers and creates a narrower product that can be assessed market by market.
Assessment criteria: J. Tanikella · Engine: GPT-5.6 Terra.
